[L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism]. 1974

N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
January 1975, Neurologia i neurochirurgia polska,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
April 1973, Die Medizinische Welt,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
November 1979, Die Medizinische Welt,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
October 1972, Fortschritte der Neurologie, Psychiatrie, und ihrer Grenzgebiete,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
September 1974, Harefuah,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
December 1972, Minerva medica,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
October 1973, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
June 1972, Wiener medizinische Wochenschrift (1946),
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
January 1976, Neurologia, neurocirugia, psiquiatria,
N Fujimori, and S Kito, and M Yamamoto, and E Itoga, and K Kosaka
January 1977, Neurologia i neurochirurgia polska,
Copied contents to your clipboard!